This strong, distinctive color works in harmony with the multicolored palette of the company’s portfolio of well-known brands. With empathy, we unearth extraordinary breakthroughs in everyday care, and with courage and conviction, we bring them to life. We boldly pursue more innovative ways of working, pioneer solutions that improve lives, and create products that create categories — then improve them again and again. Reliable fundamental data to provide unconflicted insights into the fundamentals and valuation of private and public businesses. As a provider of some of the largest consumer health products in the world, Kenvue generated nearly $15 billion in revenue in 2022 and $2.3 billion in net operating profit after tax (NOPAT).
“We believe that daily self-care rituals add up over time and have a profound cumulative impact on your wellbeing. This is the extraordinary power of everyday care. And our work is to put that power into the hands of consumers around the world,” Mongon adds. Our essential health brands have been raising standards of personal care across baby ifc markets care, wound care, oral care and sanitary protection for generations. Our skin health & beauty brands bring together next-generation science and partnerships with skin experts to create high-performance products for healthy skin. Skin health and beauty products accounted for $4.4 billion in net sales last year, or 29% of overall revenue.
- Kenvue, however, doesn’t enjoy that same luxury — its cash and cash equivalents as of the end of 2022 total $1.2 billion.
- Bringing European healthcare technologies to the North American market can potentially improve healthcare in this part of the world, open up new market opportunities for investors and expose those companies to significant growth capital.
- This article includes content from CardieX Limited, licensed for the purpose of publishing on Investing News Australia.
While you might expect the high bar set by European regulators to act as a barrier, they arguably serve more as a barometer for excellence. If a product is deemed acceptable under the strict regulatory standards of the EU, investors can rest assured it’s of the highest quality. More importantly, a company that can weather scrutiny in Europe should have little trouble going to market elsewhere.
Hydrogen Stocks: 9 Biggest Companies
“Unveiling the Kenvue brand is a defining moment for our stakeholders and an important part of the planned separation,” said Thibaut Mongon, CEO Designate, Kenvue, the planned New Consumer Health Company. “We breathe life into some of the world’s most iconic and beloved brands every day, so we harnessed that same expertise, love, and energy into developing bitbuy canada review our new corporate identity.” J&J plans to distribute the remaining shares of common stock to its shareholders later this year. Kenvue’s debut also marks the largest restructuring in J&J’s 135-year history. J&J announced the split in late 2021 as a bid to streamline operations and refocus on its pharmaceutical and medical device divisions.
Kenvue IPO: Profitable Company, Expensive Stock
In addition to healthcare, the Swiss government invests heavily in research and development across multiple sectors. As a result, even though its population totals just over 8.7 million, Switzerland holds the world’s third-highest number of patents per capita, just behind the United States and Japan. With AllergyCast®, your patients can track and record their symptoms and print their results to share with you during future visits. Overall, Kenvue said 2022 sales were “well balanced” across the company’s three business divisions. “Johnson & Johnson will continue to control the direction of our business, and the concentrated ownership of our common stock may prevent you and other shareholders from influencing significant decisions,” Kenvue said in the filing. Meanwhile, Kenvue is chock full of household names familiar to investors and the larger public, such as Tylenol, Band-Aid, Listerine, Aveeno, Neutrogena, and J&J’s namesake baby powder and shampoo.
Spin-off and IPO
Now, all investors, not just Wall Street insiders, can access trustworthy research on the earnings and valuation of stocks, bonds, ETFs, and mutual funds. Elite money managers, advisors and institutions have relied on us to lower risk and improve performance since 2004. One thing investors will like about the stock is that Kenvue stated in its prospectus that it expects to pay a quarterly cash dividend of $0.20 per share later this year. Assuming that is the case and the company pays every quarter, that would result in a yield of around 3.1% based on a share price of $26, which would be higher than the S&P 500 average of 1.7%. But while that diversification will add safety, it won’t necessarily make for a good growth investment.
Kenvue plans to pay a dividend
The company expected to price 151 million shares between $20 and $23 per share, according to a preliminary prospectus it filed with the Securities and Exchange Commission last week. We’ve always prioritized science as the core binance canada review of how we provide care, and this will never change. We are committed to continuously improving our sustainability efforts through our brands, packaging and operations, delivering on the expectations of today’s consumers.
Investors seeking to take advantage of this opportunity could do so through a holding company targeting the EU — one with plans to expose its investments to North America. Bringing European healthcare technologies to the North American market can potentially improve healthcare in this part of the world, open up new market opportunities for investors and expose those companies to significant growth capital. Formerly the Consumer Healthcare division of Johnson & Johnson,[2] Kenvue is the proprietor of well-known brands such as Aveeno,[3] Band-Aid,[4] Benadryl, Zyrtec,[5] Johnson’s,[6] Listerine,[7] Mylanta, Neutrogena,[3] Tylenol,[7] and Visine. In its S-1, Kenvue notes that the consumer health market grew at a compound annual growth rate (CAGR) of 4.8% from 2019 to 2022, and management believes the market will continue to grow at a CAGR of 3 to 4% globally through 2025. This not only generates investment capital for the healthcare technology company but also drives value for shareholders and investors. As with any market, you need to know what to look for if you’re to make smart decisions.
Lastly, although some investment firms have begun directing their attention to Europe, many startups in the region still lack the capital to take their technology to North America. While they would undeniably benefit from access to a new crop of potential investors, it’s generally more cost-effective to continue developing their technology. German-Irish medtech company LUMA Vision — formerly OneProjects — is developing a new technology platform that it believes will revolutionize the treatment of cardiac arrhythmias and atrial fibrillation. Known as VERAFEYE, the technology will leverage data analytics and advanced imaging to provide physicians with a four dimensional view of the heart.
That means less risk-taking and perhaps more conservatism, which caters to the preferences of dividend investors rather than to those looking for an aggressive growth stock. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation. The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company.
Medical startups in North America tend to receive significantly higher valuations than they would in other markets. While this is immensely beneficial for the startups themselves, it can present a considerable barrier to entry for investors. Based in Austria, Biome Diagnostics’ BiomeOne utilizes microbiome analysis to help determine how a cancer patient will likely respond to immunotherapy. It is the first diagnostic test of its kind, with multiple potential applications in personalized healthcare. The startup was recently granted the prestigious Alex Casta Audience Award via the EIT Health Catapult 2023 competition.
Our top priority is helping you serve your patients and drive better health outcomes. And products in the essential health division, including baby products, mouthwash and dental rinses, sanitary protection and wound care, saw $4.6 billion in net sales, representing 31% of all-in revenue. KVUE would be worth just $18/share today – a 16% downside to the midpoint IPO price range. In this scenario, Kenvue’s revenue would still grow to $19.7 billion in 2029, or 4% compounded annually. This scenario also implies the company would earn $3.1 billion in NOPAT and grow NOPAT 4% compounded annually through 2029. In other words, even if Kenvue improves margins and grows revenue at the high end of management’s estimate, the stock is worth only $18/share.
